Effects of UTI on alleviating hypertension, proteinuria and inflammatory response in PE rats

doi:10.11958/20220357

Abstract

Abstract:

Objective To explore the effectiveness and feasibility of ulinastatin (UTI) in the treatment of pre-eclampsia (PE) rats. Methods Fifty-six SD rats at 12 days of gestation (G12) were randomly divided into 4 groups: the control group (group C, intraperitoneal injection of normal saline), the PE group (intraperitoneal injection of L-NAME 200 mg/kg), the PE+U₁ group (PE rats injected with UTI 5 000 IU·kg^-1·d^-1) and the PE+U₂ group (PE rats injected with UTI 10 000 IU·kg^-1·d^-1). The systolic blood pressure (SBP) was measured on G12, G13, G15, G17 and G19, and urinary protein in 24 hours was measured on G12 and G19. The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), von Willebrand factor (vWF) and placental growth factor (PLGF) in plasma and placenta were measured on G20. Results Compared with the group C, the SBP and urinary protein levels were increased in the PE group, the PE+U₁ group and the PE+U₂ group. UTI decreased the SBP and urinary protein levels in PE rats, and the urinary protein level was lower in the PE+U₂ group (P<0.05). Compared with the group C, TNF-α and IL-6 levels were increased in the PE group and the PE+U₁ group, and only placental TNF-α level was increased in the PE+U₂ group (P<0.05). UTI reduced TNF-α and IL-6 levels in PE rats. The plasma and placental levels of TNF-α, IL-6 and the placental IL-6 level were lower in the PE+U₂ group (P<0.05). Compared with the group C, the PLGF levels were reduced, the vWF levels were increased in the PE group and the PE+U₁ group, but the vWF levels were only increased in the PE+U₂ group (P<0.05). UTI increased PLGF levels and reduced vWF levels in PE rats, and the levels of vWF were lower in the PE+U₂ group (P<0.05). Conclusion UTI can effectively inhibit inflammatory response in plasma and placenta of PE rats, reduce vascular endothelial injury, and alleviate hypertension and proteinuria of PE rats. The therapeutic effect of 10 000 IU·kg^-1·d^-1 UTI is better than 5 000 IU·kg^-1·d^-1.

Key words: pre-eclampsia, hypertension,pregnancy-induced, proteinuria, inflammatory response, ulinastatin

CLC Number:

R714.252

Figures/Tables 5

References 19

[1]	WOJTOWICZ A, ZEMBALA-SZCZERBA M, BABCZYK D, et al. Early- and late-onset preeclampsia:A comprehensive cohort study of laboratory and clinical findings according to the New ISHHP Criteria[J]. Int J Hypertens, 2019, 2019:4108271. doi: 10.1155/2019/4108271.
[2]	WANG H, LASZLO K D, GISSLER M, et al. Maternal hypertensive disorders and neurodevelopmental disorders in offspring:a population-based cohort in two Nordic countries[J]. Eur J Epidemiol, 2021, 36(5):519-530. doi: 10.1007/s10654-021-00756-2.
[3]	NIRUPAMA R, DIVYASHREE S, JANHAVI P, et al. Preeclampsia:Pathophysiology and management[J]. J Gynecol Obstet Hum Reprod, 2021, 50(2):101975. doi: 10.1016/j.jogoh.2020.101975.
[4]	FENG Z, SHI Q, FAN Y, et al. Ulinastatin and/or thymosin α1 for severe sepsis:A systematic review and Meta-analysis[J]. J Trauma Acute Care Surg, 2016, 80(2):335-340. doi: 10.1097/TA.0000000000000909.
[5]	POON L C, SHENNAN A, HYETT J A, et al. The international federation of gynecology and obstetrics(FIGO)initiative on pre-eclampsia:A pragmatic guide for first-trimester screening and prevention[J]. Int J Gynaecol Obstet, 2019, 145(Suppl 1):1-33. doi: 10.1002/ijgo.12802.
[6]	WANG Z, WANG P, WANG Z, et al. MiRNA-548c-5p downregulates inflammatory response in preeclampsia via targeting PTPRO[J]. J Cell Physiol, 2019, 234(7):11149-11155. doi: 10.1002/jcp.27758.
[7]	UDENZE I, AMADI C, AWOLOLA N, et al. The role of cytokines as inflammatory mediators in preeclampsia[J]. Pan Afr Med J, 2015, 20:219. doi: 10.11604/pamj.2015.20.219.5317.
[8]	SLJIVANCANIN JAKOVLJEVIC T, KONTIC-VUCINIC O, NIKOLIC N, et al. Glutathione-S-transferase M1 polymorphism and pro-inflammatory cytokines tumour necrosis factor-alpha and interleukin-1beta are associated with preeclampsia in Serbian women[J]. Am J Reprod Immunol, 2019, 81(5):e13105. doi: 10.1111/aji.13105.
[9]	DAS U N. Cytokines,angiogenic,and antiangiogenic factors and bioactive lipids in preeclampsia[J]. Nutrition, 2015, 31(9):1083-1095. doi: 10.1016/j.nut.2015.03.013.
[10]	DING H, JIANG Y, JIANG Y, et al. Ulinastatin attenuates monocyte-endothelial adhesion via inhibiting ROS transfer between the neighboring vascular endothelial cells mediated by Cx43[J]. Am J Transl Res, 2020, 12(8):4326-4336.
[11]	FANG M, ZHONG W H, SONG W L, et al. Ulinastatin ameliorates pulmonary capillary endothelial permeability induced by sepsis through protection of tight junctions via inhibition of TNF-alpha and related pathways[J]. Front Pharmacol, 2018, 9:823. doi: 10.3389/fphar.2018.00823
[12]	黄春燕. 子痫前期血清诱导血管内皮细胞产生炎性因子与乌司他丁的阻断效应[D]. 南宁: 广西医科大学, 2012.
	HUANG C Y. The product of inflammatory cytokines in cultured human umbilical endothelial cells induced by sera of preeclampsia and the inhibition of unlinastatin[D]. Nanning: Guangxi Medical University, 2012.
[13]	WEI F, LIU S, LUO L, et al. Anti-inflammatory mechanism of ulinastatin:Inhibiting the hyperpermeability of vascular endothelial cells induced by TNF-α via the RhoA/ROCK signal pathway[J]. Int Immunopharmacol, 2017, 46:220-227. doi: 10.1016/j.intimp.2017.03. 007.
[14]	STEPAN H, HUND M, ANDRACZEK T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia:the angiogenic-placental syndrome[J]. Hypertension, 2020, 75(4):918-926. doi: 10.1161/HYPERTENSIONAHA.119.13763.
[15]	BIAN Z, SHIXIA C, DUAN T. First-trimester maternal serum levels of sFLT1, PGF and ADMA predict preeclampsia[J]. PLoS One, 2015, 10(4):e0124684. doi: 10.1371/journal.pone. 0124684.
[16]	GUNGOR Z B, EKMEKCI H, TUTEN A, et al. Is there any relationship between adipocytokines and angiogenesis factors to address endothelial dysfunction and platelet aggregation in untreated patients with preeclampsia?[J]. Arch Gynecol Obstet, 2017, 296(3):495-502. doi: 10.1007/s00404-017-4461-2.
[17]	OTSUKI K, KAWABATA I, MATSUDA Y, et al. Randomized trial of the efficacy of intravaginal ulinastatin administration for the prevention of preterm birth in women with a singleton pregnancy and both cervical shortening and inflammation of lower genital tract[J]. J Obstet Gynaecol Res, 2019, 45(1):86-95. doi: 10.1111/jog.13796.
[18]	赵若光, 陈彦青, 姚玉笙, 等. 乌司他丁对剖宫产患者凝血及血小板聚集功能的影响[J]. 临床麻醉学杂志, 2011, 27(6):566-568.
	ZHAO R G, CHEN Y Q, YAO Y S, et al. Effect of ulinastatin on coagulation and platelet aggregation in cesarean section[J]. J Clin Anesthesiol, 2011, 27(6):566-568.
[19]	YU Z, WANG J, ZHANG P, et al. Ulinastatin attenuates vascular endothelial cell damage in pregnant women with severe pre-eclampsia[J]. An Acad Bras Cienc, 2019, 91(3):e20180746. doi: 10.1590/0001-3765201920180746.

组别		n	G12		G13
C组		14	112.86±5.87		110.14±6.06
PE组		12	111.75±5.97		133.53±6.61^a
PE+U₁组		13	110.15±7.14		123.92±7.19^ab
PE+U₂组		13	113.39±5.32		118.23±8.88^ab
F			0.716		23.670^＊＊
组别	G15			G17		G19
C组	110.79±5.83			111.29±4.84		116.50±6.50
PE组	147.00±5.78^a			142.58±6.67^a		144.67±4.36^a
PE+U₁组	128.23±8.06^ab			126.69±7.78^ab		129.92±7.15^ab
PE+U₂组	122.02±6.04^ab			120.00±7.70^ab		123.31±5.62^abc
F	69.610^＊＊			47.980^＊＊		50.460^＊＊

组别		n	G12		G13
C组		14	112.86±5.87		110.14±6.06
PE组		12	111.75±5.97		133.53±6.61^a
PE+U₁组		13	110.15±7.14		123.92±7.19^ab
PE+U₂组		13	113.39±5.32		118.23±8.88^ab
F			0.716		23.670^＊＊
组别	G15			G17		G19
C组	110.79±5.83			111.29±4.84		116.50±6.50
PE组	147.00±5.78^a			142.58±6.67^a		144.67±4.36^a
PE+U₁组	128.23±8.06^ab			126.69±7.78^ab		129.92±7.15^ab
PE+U₂组	122.02±6.04^ab			120.00±7.70^ab		123.31±5.62^abc
F	69.610^＊＊			47.980^＊＊		50.460^＊＊

组别	n	G12	G19
C组	14	91.07±12.60	89.71±11.65
PE组	12	84.25±9.95	140.42±14.36^a
PE+U₁组	13	91.23±10.37	128.08±8.56^ab
PE+U₂组	13	84.46±10.34	100.85±11.16^abc
F		1.673	51.350^＊＊

组别	n	G12	G19
C组	14	91.07±12.60	89.71±11.65
PE组	12	84.25±9.95	140.42±14.36^a
PE+U₁组	13	91.23±10.37	128.08±8.56^ab
PE+U₂组	13	84.46±10.34	100.85±11.16^abc
F		1.673	51.350^＊＊

组别		血浆			胎盘
组别	n	TNF-α（ng/L）	IL-6（ng/L）	n	TNF-α	IL-6
C组	7	21.64±6.43	16.80±4.94	14	0.31±0.14	0.40±0.09
PE组	6	69.94±12.92^a	41.37±7.83^a	12	1.06±0.09^a	0.97±0.21^a
PE+U₁组	7	49.55±10.59^ab	27.01±4.62^ab	13	0.87±0.11^ab	0.68±0.18^ab
PE+U₂组	7	34.05±6.02^bc	19.97±2.97^b	13	0.71±0.12^abc	0.51±0.11^bc
F		32.660^＊＊	25.790^＊＊		95.860^＊＊	34.580^＊＊